OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALLKathryn Evans, Richard B. Lock, Lisa McDermott et al.|Clinical Cancer Research|2019Cited by 53